In tumor-bearing mice, combination therapy with both toosendanin and ICI (PD-1 and CTLA-4 blockade) outperformed toosendanin or ICI administered alone, slowing tumor growth and improving median survival [53] (Table 1). Here, CTLA4 is linked to neoplasm.